Researchers Submit Patent Application, "Engineered Uridine Phosphorylase Variant Enzymes", for Approval (USPTO 20240132858).
In: Medical Letter on the CDC & FDA, 2024-05-17, S. 2022-2022
serialPeriodical
Zugriff:
The given text is a patent application for "Engineered Uridine Phosphorylase Variant Enzymes" submitted by inventors Jessica Anna Hurtak, Anders Matthew Knight, and Jonathan Vroom. The application addresses the need for improved methods of synthesizing substrates and intermediates used in the treatment of cancer and viral infections. It describes engineered enzymes with specific amino acid substitutions or sets of substitutions that enhance their efficiency in producing pharmaceutical compounds. The patent application provides detailed information on the polynucleotide and polypeptide sequences of these enzymes, as well as their specific positions and substitutions. For more information, readers can refer to the full patent application. [Extracted from the article]
Copyright of Medical Letter on the CDC & FDA is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Engineered Uridine Phosphorylase Variant Enzymes", for Approval (USPTO 20240132858).
|
---|---|
Zeitschrift: | Medical Letter on the CDC & FDA, 2024-05-17, S. 2022-2022 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1532-4648 (print) |
Schlagwort: |
|
Sonstiges: |
|